Hutchmed (china) Share Discussion Threads

[thornyone] 03/9/2018 17:05

Hi Patrick. Aren't you confusing Fruquintinib with Furazolinib? Or are they one and the same?

[patrick0999] 03/9/2018 16:43

Chinese media Reports about fruquintinib will launch in coming 1-2 months

[nerdofsteel] 03/9/2018 14:58

Posting this whilst standing on a plaza that sits halfway between the old HWL HQ Building on Harcourt Rd and the CK Centre on Queens Rd Central Hong Kong. Looking forward to material news shortly.....

[nerdofsteel] 29/8/2018 18:01

Here's another great article on the rise of China's Biotech industry, posted today

[nerdofsteel] 29/8/2018 18:00

Thankyou Lauders, great post, very useful and interesting

[lauders] 29/8/2018 12:24

Not included in one of the 3 mentioned but still good to read this bit:

The numbers are staggering. Over the next six years, the biotech market is expected to add $593 billion in value – a 419% leap over the size of today’s biotech market.

Growth like this is why Wall Street is rushing hand over foot to buy the most lucrative biotech companies available. In just the last eight months, biotech acquisitions have totaled an astonishing $17 billion.

But not every biotech stock is worth owning. Far from it.



Of course "expectations" might not meet "reality", but with China in the mix and their population I would think that the chances are pretty strong and HCM should be on the list. I am of course completely biased!

PS. Is HCM a biopharmaceutical or biotech company or both?

PPS. Not sure anyone posted this yet:

[sportii] 24/8/2018 12:30

Hi,
If you have come across any such articles (about fruquintinib launch in Chinese media), please post the links here. Thanks

[nerdofsteel] 23/8/2018 08:10

Motley Fool yesterday

"Don’t worry about the State Pension! These 2 pharma stocks could make you VERY wealthy"



Let's hope so!

[nerdofsteel] 23/8/2018 08:08

Some great commentary from our Chief Executive on Chi-Med and Chinese Biotech

[patrick0999] 22/8/2018 10:06

See many Chinese media start to report the launch of fruquintinib in the coming months. Should be part of PR and marketing before the product actually on sell. Anyway, all positive reports.

[nerdofsteel] 21/8/2018 11:12

Another Good find, thanks Lauders!

[lauders] 21/8/2018 08:24

Well, AZ tagrisso news today so hopefully some will come HCM's way in the "near" future:

[nerdofsteel] 18/8/2018 12:20

Thanks for the heads up on the latest Edison note Laila



"We believe HCM can start to initiate its global commercial strategy based initially
on fruquintinib, but with a view to leveraging the late-stage oncology portfolio given multiple potential drug approvals in 2020/21. We therefore expect HCM to become a major China and international oncology company"

[nerdofsteel] 17/8/2018 20:50

I continue to buy

[nerdofsteel] 17/8/2018 20:49

thx for that Laila - interesting this note comes so quickly after the last one

£73 - by year end IMO

[100laila] 17/8/2018 10:41

new Edison note out

main elements:-

Expansion of US and international operations

HCM has established an office in New Jersey, US and has appointed a US CMO and a Head of International Operations (both individuals are experienced industry veterans). This highlights HCM’s commitment to its global R&D strategy; it has the financial strength ($416.9m in available resources as of 30 June 2018) to initiate its global commercial strategy, which is critical given the late clinical development stage of the R&D pipeline and the necessity to expand its clinical trial programmes internationally to maximise economic returns.

Savolitinib potential for accelerated China approval

Highly encouraging data from the ongoing savolitinib Phase II (China) NSCLC- MET exon14 mutation/deletion patients have prompted discussions with the Chinese National Drug Administration (CNDA) on an approval pathway. The agency has indicated that if Phase II data complete with patient ORR in excess of 50%, this Phase II trial should be sufficient for submitting an NDA in this indication.

Financials: Guidance updated, higher R&D expenses

HCM has updated its FY18 net loss guidance to $39-72m (from $19-52m), reflecting $20m higher than anticipated adjusted R&D expenses (non-GAAP) due to the rapid expansion of operations, higher clinical trial costs in China and the impact of employee share incentive schemes. All other guidance is unchanged.

Valuation: $6.4bn (£73.3/share, $48.2/ADS)

Our increased valuation of $6.4bn or £73.3/share (from $6.4bn or £71.0/share) results from rolling forward our DCF and updating FX rates, offset by a lower net cash position at 30 June 2018 and higher R&D in 2018 and 2019. We value the Innovation Platform (IP) at $4,780.5m and placing the Commercial Platform’s (CP) 2018e share of net profit on a 20.4x rating gives $848.2m (945p/share).

[prince7652] 16/8/2018 12:11

Adding in small quantities

[shaker44] 16/8/2018 08:25

just bought more at 4498. amazed

[nerdofsteel] 16/8/2018 08:08

Brad Loncar is a massive fan of Chi-Med and was in HK 2 weeks ago meeting the Company and hosting an investment forum

Like WW2 the Americans are late and have only just woken up to the massive market potential in China and the huge growth of Chinese Biotechs!

[lauders] 16/8/2018 01:52

Thanks for that NofS! Stinker of a day where HCM is concerned. Gave a lot back. Volatility is set to remain until the big news comes and then hopefully we will be taken to another higher level!

Also found from your last link:

[nerdofsteel] 15/8/2018 13:49

$HCM new NASDAQ China ETF begins trading today folks and HCM is in the mix BULLISH hxxps://loncarfunds.com/chna-holdings/

[nerdofsteel] 15/8/2018 09:07

yes, and interesting they rarely feature specifically in updates or Company presentations but continue to deliver growing revenues and profits which help fund the pipeline development......

First NDA looming ;o-)

[lauders] 14/8/2018 02:50

Learnt something new from the report too:

Hutchison Healthcare Limited (“HHL”) and Hutchison Hain Organic Holdings Limited (“HHOH”): HHL, HHOH and other minor entities are subsidiaries involved in the commercialization of health-related consumer products. Sales of such products in the first half of 2018 grew by 14% to $20.6 million (H1 2017: $18.1m)driven in part by growth of the Zhi Ling Tong® and Earth’s Best® infant nutrition products.

Did not realize HCM had these businesses and found a few old links explaining the links:

[lauders] 14/8/2018 02:11

The interim report is available here:

Recent, as added 10th August from what I can see.


I like the Chairman's closing paragraphs in his statement:

We are now looking closely into multiple opportunities to combine our highly selective TKIs with both PD-1 and PD-L1 immunotherapy agents and will strive to make progress during the second half of 2018, via collaboration, in this very high potential arena.

We have expanded our U.S./ex-Asia operations, including our office in New Jersey, and continue to recruit seasoned talent to manage the progress of our unpartnered compounds through proof-of-concept,registration trials, and market launch in territories outside of Asia.

Chi-Med has a clear and ambitious aim to bring three of our drugs through approval over the next approximately three years. We believe we are adequately structured and resourced to support this aim. In the longer term, we intend to continue to emerge as a world-class innovator based in China, bringing our assets to both the China and global markets. We have confidence in our ability to achieve these aims.

[mastermatto] 13/8/2018 12:20

Nerd - I really like DividendBot. Do you know of a similar tool that works for UK shares?